This webinar discusses the approval of elotuzumab in combination with two other therapies (lenalidomide and dexamethasone) to treat people with multiple myeloma. We will also discuss the significance of the breakthrough therapy, priority review and orphan drug designations for elotuzumab by the FDA.
Gary Lyman, MD, MPH, FASCO, FACP, FRCP Co-Director, Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences & Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Professor of Medicine, Public Health and Pharmacy, University of Washington, Seattle, WA
Nicole J. Gormley, MD Acting Clinical Team Lead, Scientific Liaison for Multiple Myeloma, Division of Hematology Products, U.S. Food and Drug Administration, Silver Spring, MD
Sagar Lonial, MD, FACP Chair and Professor, Department of Hematology and Medical Oncology, Chief Medical Officer, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA